ClinicalTrials.gg
Active, not recruitingNCT07448662COLBRAINUpdated Mar 4, 2026

Local Treatment Strategies for Brain Metastases of Colorectal Cancer

An observational study in Colorectal Cancer and Brain Metastases, Adult, sponsored by Blokhin's Russian Cancer Research Center. Active, not recruiting at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Blokhin's Russian Cancer Research Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
700
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Colorectal Neoplasms with a site in Russia — 4 open to participants now, 13 under way, 2 of them phase 3. Colorectal Neoplasms · Russia.

Started
2026
with 1 other
Observational
2 of 22
none open now
Primary completion
2027-10
later than 9 of 12 live
Registered
18th of 22
by date
Lead sponsor
5 of 22
Blokhin's Russian Cancer Research Center

Among the 22 studies in Colorectal Neoplasms with a site in Russia, this one is one of 2 that started in 2026, is one of 2 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 18th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 22 studies in Colorectal Neoplasms with a site in Russia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Colorectal Neoplasms with a site in Russia, or all of them as a file.
02

Study summary

COLBRAIN trial is an international (2 countries) observational, multicenter (15 centers) retrospective cohort study designed to investigate local treatment strategies for brain metastases of colorectal cancer.

Read the detailed description

Brain metastases (BM) from colorectal cancer (CRC) are a rare event, reported in less than 3% of patients with CRC. This course is associated with a dismal prognosis, and treatment of these patients remains challenging. The rarity of the event complicates research into both the effectiveness of local treatment methods and long-term oncological outcomes. Published studies are largely limited to single-center series with non-representative small patient cohorts, making it difficult to assess the reasons for such unsatisfactory treatment results.

Despite its rarity, there is growing evidence that the incidence of BM from CRC is increasing. Although direct epidemiological data are limited, many experts believe the detection rate has risen over the past quarter-century. This trend is likely multifactorial, attributed to advances in neuroimaging techniques and improved life expectancy due to the evolution of systemic therapy strategies.

However, this increase in detection has not translated into improved outcomes. Central nervous system (CNS) involvement in CRC remains associated with a dismal prognosis; median overall survival from the time of progression ranges from 2 to 5 months and has not substantially improved over recent decades. The aggressive disease course and the unmet clinical need for effective therapeutic strategies highlight the importance of large-scale, real-world data.

The primary objective of this study is to evaluate, in a large multi-institutional real-world cohort, the effectiveness of the following local treatment modalities for CRC BM:

  1. Neurosurgical resection (NRS):

    • En-bloc resection (EBR)
    • Total piecemeal resection (TPR)
    • Subtotal (SPR) or partial piecemeal resection (PPR)
    • Extent of resection unknown
  2. Radiotherapy (RT):

    • Stereotactic radiosurgery (SRS)
    • Staged stereotactic radiosurgery (stSRS)
    • Stereotactic radiotherapy (hypofractionated) (SRT)
    • Whole-brain radiotherapy (WBRT)
  3. Combined local treatment modalities:

    • NRS with postoperative WBRT
    • NRS with postoperative SRT/SRS
    • Preoperative SRS followed by NRS
    • Combination radiotherapy (SRS and WBRT, SRT and WBRT, SRS and SRT)
  4. No local treatment

Investigators from a multi-institutional consortium of 15 major cancer centers across Russia and Belarus have initiated a collaborative effort to create, to the best of our knowledge, the largest and most comprehensive retrospective dataset of patients with CRC BM described to date. This dataset will pool clinical, pathological, and treatment-related data from patients diagnosed over the past quarter-century (2000-2025). Data to be collected for each patient will include:

  1. Demographics and Baseline Characteristics

    • Sex (male/female)
    • Age at primary cancer diagnosis (years, median with range)
    • Age at BM diagnosis (years, median with range)
  2. Primary Tumor Characteristics

    • TNM classification (T, N, M categories with subcategories, including X when unknown)
    • Disease stage at initial diagnosis (I-II, III, IV, unknown)
    • History of primary tumor resection (yes/no/unknown)
    • Primary tumor sidedness:

      • Right-sided (cecum, ascending colon, hepatic flexure, transverse colon)
      • Left-sided (splenic flexure, descending colon, sigmoid colon, rectosigmoid junction, rectum)
      • Unknown
    • Primary tumor location (cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, rectosigmoid junction, rectum, multiple tumors of colon, unknown)
  3. Extracranial Disease Burden:

    • At initial cancer diagnosis:

      • Number of extracranial organ sites involved (1, 2, ≥ 3, unknown)
      • Location of extracranial metastases (liver, lung, peritoneum, bone, adrenal glands, soft tissues, distant lymph nodes, other; with specification of exclusive vs. combined involvement)
    • At the time of BM diagnosis:

      • Presence of extracranial metastases (yes/no/unknown)
      • Number of extracranial organ sites involved (1, 2, ≥ 3, unknown)
      • Location of extracranial metastases (liver, lung, peritoneum, bone, adrenal glands, soft tissues, distant lymph nodes, other; with specification of exclusive vs. combined involvement; including "brain-exclusive" disease)
      • Activity of extracranial disease (stable, progressing, brain-exclusive, unknown)
  4. Intracranial Tumor Characteristics

    • Number of BM at diagnosis (median with range; categorized as solitary vs. ≥ 2)
    • Location relative to the tentorium (supratentorial, infratentorial, both)
    • For solitary BM: specific localization (frontal, temporal, parietal, occipital lobe; cerebellum; left/right hemisphere; unknown)
    • Cumulative intracranial tumor volume (CITV) (cm³, median with range; categorized into clinically relevant volume groups)
    • Largest intracranial tumor volume (LITV) (cm³, median with range; categorized into clinically relevant volume groups)
    • Maximum diameter of the largest intracranial tumor (cm, median with range; categorized into clinically relevant diameter groups)
    • Radiological features (present/absent/unknown): Perifocal edema, Mass effect, Dislocation syndrome, Ventricular compression (lateral, III, IV), Brainstem compression, Intratumoral hemorrhage, Intratumoral necrosis, Leptomeningeal disease (LMD), Occlusive hydrocephalus, Bone destruction, Cerebellar tonsil herniation
  5. Clinical Presentation

    • Timing of BM diagnosis:

      • Synchronous (within 60 days of primary tumor diagnosis or as initial presentation)
      • Metachronous (> 60 days after primary tumor diagnosis)
      • Unknown
    • Neurological symptoms at BM diagnosis (symptomatic, asymptomatic, unknown)
    • Presence of neurological deficit at BM diagnosis (yes/no/unknown)
    • Neurological syndromes at BM diagnosis (global cerebral symptoms (headache, nausea, vomiting, dizziness), aphasic, dysarthric, pyramidal, sensory, extrapyramidal, cerebellar/vestibulo-ataxic, bulbar, pseudobulbar, paroxysmal, cognitive, brainstem, visual, meningeal, occlusive, behavioral, unknown)
    • ECOG performance status at BM diagnosis (0-1, 2-3, unknown)
  6. Molecular Profile (where available)

    • Primary tumor:

      - RAS status (mutant/wild-type/unknown; specify codon if available)

      - BRAF status (mutant/wild-type/unknown; specify mutation if available)

      • dMMR/MSI status (MSI/MSS/unknown)
      • HER2 status (positive/negative/unknown)
    • Brain metastases:

      - RAS status (mutant/wild-type/unknown; specify codon if available)

      - BRAF status (mutant/wild-type/unknown; specify mutation if available)

      • dMMR/MSI status (MSI/MSS/unknown)
      • HER2 status (positive/negative/unknown)
  7. Treatment-Related Data

    ◾ Lines of systemic therapy prior to BM diagnosis (number; categorized as 0, 1, 2, 3, 4, ≥ 5, unknown)

    • Lines of systemic therapy after first local treatment (number)
    • First local treatment modality (see detailed list below)
    • Number of local treatments per patient (median with range)
    • For radiotherapy:

      • Radiation therapy device (Leksell Gamma Knife, Accuray CyberKnife, Varian TrueBeam/Novalis Tx, non-stereotactic linac, other)
      • Biologically effective dose (BED) (Gy, median with range)
      • Equivalent dose (EQD2) (Gy, median with range)
  8. Institutional and Period Data

    • Institution type (federal center, reference center, regional center)
    • Treatment period (by year of primary cancer diagnosis):

      - 2000-2010

      • 2011-2020
      • 2021-2025

Primary Endpoints:

  1. Overall Survival (OS): Defined as the time from the date of brain metastasis (BM) diagnosis to the date of death from any cause or last follow-up (censored).
  2. Time to Intracranial Progression (TTIP): Defined as the time from the date of initial colorectal cancer (CRC) diagnosis to the date of first BM detection. Based on this interval, patients will be categorized into two groups:

    - Synchronous BM: BM diagnosed either prior to or within 2 months (≤ 60 days) of the primary tumor diagnosis.

    - Metachronous BM: BM diagnosed more than 2 months (> 60 days) after the primary tumor diagnosis.

  3. Central Nervous System Progression-Free Survival (CNS-PFS): Defined as the time from the date of first local treatment for BM to the date of subsequent intracranial progression or last instrumental follow-up (censored). Subsequent intracranial progression includes:

    • Continued growth of the treated lesion (≤ 6 months thereof);
    • Local recurrence of the treated lesion (> 6 months thereof);
    • Development of new distant intracranial lesions.

Secondary Endpoints:

  1. Overall Survival from Initial Diagnosis: Time from initial CRC diagnosis to death from any cause or last follow-up.
  2. Cancer-Specific Survival: Time from BM diagnosis to death from cancer progression (intracranial and/or extracranial), accounting for death from other causes as a competing event.
  3. Cumulative Incidence of Death from Intracranial Progression: Death directly attributable to neurological complications resulting from progressive intracranial disease, analyzed using competing risks methodology with death from other causes as competing events.
  4. Cumulative Incidence of Death from Extracranial Progression: Death attributable to systemic disease progression in the presence of controlled intracranial disease, analyzed using competing risks methodology.
  5. Cumulative Incidence of Death from Other Causes: Death from causes unrelated to cancer progression, analyzed using competing risks methodology.
  6. Cumulative Incidence of Repeat Local Interventions: The cumulative proportion of patients undergoing any additional local treatment (neurosurgery or radiotherapy) for intracranial disease progression following initial local therapy. This endpoint captures the total burden of repeat procedures required for recurrent or new intracranial lesions during follow-up. Death without a repeat intervention is treated as a competing event in the analysis.

    Statistical Analysis. All statistical analyses will be performed using IBM SPSS Statistics (version 29.0) and STATA (version 17.0, StataCorp LLC). A two-sided p-value \< 0.05 will be considered statistically significant.

    - Descriptive Statistics. Categorical variables will be presented as absolute frequencies (n) and relative frequencies (%). Continuous variables will be assessed for normality. Normally distributed variables will be presented as mean with standard deviation (SD); non-normally distributed variables will be presented as median with interquartile range (IQR) or full range. The frequency of missing data will be reported for each variable. Where appropriate, multiple imputation using chained equations (MICE) will be considered to address missing data and minimize bias.

    - Survival Analysis. Survival curves will be estimated using the Kaplan-Meier method. Median survival times with 95% confidence intervals (CI) will be reported. Comparison of survival curves between groups will be performed using the log-rank test and, where appropriate, the Breslow-Wilcoxon test.

    For analyses of cause-specific death, competing risks methodology will be employed to estimate the cumulative incidence of death from intracranial progression, extracranial progression, and other causes, with death from competing causes treated as a competing event.

    - Univariable and Multivariable Analysis. Univariable analysis will be performed to identify potential prognostic factors associated with survival outcomes. For categorical variables, the log-rank test will be used. For continuous variables, univariable Cox proportional hazards regression will be performed.

    Variables with p \< 0.10 on univariable analysis, as well as clinically relevant factors regardless of significance, will be entered into multivariable Cox proportional hazards regression models to identify independent prognostic factors. The proportional hazards assumption will be tested. Results will be presented as hazard ratios (HR) with 95% CI.

    - Preplanned subgroup analyses will be performed based on key variables such as local treatment modality, molecular profile, primary tumor sidedness, timing of brain metastases (synchronous vs. metachronous), and presence of extracranial disease.

    Specific Analyses:

    • Analysis of growth kinetics: In patients with available serial imaging, volumetric growth rate (VGR, cm³/day) and volume doubling time (VDT, days) will be calculated. These parameters will be correlated with clinical, molecular, and outcome variables.
    • Radionecrosis analysis: In patients receiving radiotherapy, the cumulative incidence and time to radionecrosis (TTRN) will be assessed and correlated with treatment modality, dose, volume, and molecular profile.
    • Temporal trends: Outcomes and treatment patterns will be compared across three time periods (2000-2010, 2011-2020, 2021-2025) to assess changes in practice and survival over time.
    • Institutional analysis: Outcomes will be compared across institution types (federal, reference, regional centers) to explore potential disparities in care.
    • GPA index validation: The prognostic accuracy of established Graded Prognostic Assessment (GPA) indices will be evaluated in this cohort and compared with any novel prognostic models developed from this data.

    Handling of Missing Data. The proportion of missing data will be reported for all variables. Patterns of missingness will be explored. Where appropriate and assuming data are missing at random, multiple imputation using chained equations (MICE) will be performed to impute missing values for key variables in multivariable models.

    The results of this large-scale, international study aim to provide high-level evidence to guide clinical decision-making and pave the way for personalized treatment approaches for this rare but challenging patient population.

03

Conditions studied

  • Colorectal Cancer
  • Brain Metastases, Adult

Keywords

  • Colorectal cancer
  • Colon cancer
  • Rectal cancer
  • Brain metastases
  • Brain metastasis
  • Central nervous system metastases
  • CNS
  • Neurosurgery
  • En-bloc resection
  • Piecemeal resection
  • Stereotactic radiosurgery
  • SRS
  • Staged stereotactic radiosurgery
  • Stereotactic radiotherapy
  • SRT
  • Hypofractionated radiotherapy
  • Whole-brain radiotherapy
  • WBRT
  • Radiotherapy
  • Local treatment
  • Cohort study
  • Observational study
  • Retrospective study
  • Real-world data
  • RWD
  • Overall survival
  • OS
  • Time to intracranial progression
  • TTIP
  • CNS-PFS
  • GPA
  • RANO-BM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients (≥ 18 years) with histologically confirmed colorectal adenocarcinoma and radiologically ± histologically documented brain metastases.

Patients with synchronous or metachronous multiple primary tumors confined to the colon or rectum are eligible. Patients referred after initial local treatment for brain metastases are included provided that complete documentation of the first treatment modality is available.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 18 years or older;
  • confirmed epithelial of the colon or rectum (colorectal adenocarcinoma). Patients with synchronous or metachronous multiple primary tumors within the colon or rectum are eligible;
  • Radiologically ± histologically confirmed , including:

    • Solid brain parenchymal
    • (LMD)
    • Both solid metastases and LMD

Exclusion criteria

Exclusion Criteria:

  • Synchronous or metachronous multiple primary (MPM) involving sites other than the colon or rectum
  • Primary tumor located outside the gastrointestinal tract;
  • confirmed non-epithelial gastrointestinal malignancy (e.g., neuroendocrine tumors, sarcoma, gastrointestinal stromal tumor, lymphoma);
  • Isolated spinal cord involvement without brain parenchymal ;
  • Incomplete medical records precluding assessment of at least one primary endpoint (OS, TTIP, or CNS-PFS). Patients with available data for any primary endpoint are eligible, even if other clinical details are missing.
  • Prior local treatment for at an outside institution with no available records, precluding determination of the first local treatment modality
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
700 participants (actual)
Patient registry
No

Groups and cohorts

  • Eligible Patients

    Adult patients (≥ 18 years) with histologically confirmed colorectal adenocarcinoma and radiologically ± histologically documented brain metastases

    Procedure: Neurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR) · Radiation: Radiotherapy (RT): Stereotactic Radiosurgery/Radiotherapy (SRS/SRT), Whole-Brain Radiotherapy (WBRT) · Other: Combined Local Treatment Modalities · Other: No Local Treatment

Interventions

  • ProcedureNeurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR)

    Patients in this cohort underwent neurosurgical resection as the primary local treatment for brain metastases. Surgical approaches include: * En-bloc resection (EBR): gross-total removal of the tumor as a single, intact specimen with no residual disease on postoperative MRI; * Total piecemeal resection (TPR): gross-total removal of the tumor in multiple fragments with no residual disease on postoperative MRI * Subtotal (SPR) or partial (PPR) piecemeal resection: incomplete removal of the tumor, with macroscopic residual disease on postoperative MRI. This includes: * Subtotal resection: 75-90% of tumor volume removed * Partial resection: 30-75% of tumor volume removed * Extent of resection unknown: surgical resection performed, but the precise extent could not be determined from available records

  • RadiationRadiotherapy (RT): Stereotactic Radiosurgery/Radiotherapy (SRS/SRT), Whole-Brain Radiotherapy (WBRT)

    Patients in this cohort received radiotherapy as the primary local treatment modality for brain metastases. Treatment modalities include: * Stereotactic radiosurgery (SRS): single-fraction, high-precision radiation with a prescribed dose \> 12 Gy; * Staged stereotactic radiosurgery (stSRS): radiosurgery delivered in 2-3 stages, typically 2-4 weeks apart, allowing for tumor volume reduction between stages; * Stereotactic radiotherapy (hypofractionated) (SRT): stereotactic radiation delivered in multiple fractions, including: * 3 fractions (single dose 7-9 Gy, total dose 21-27 Gy); * 5 fractions (single dose 6-7 Gy, total dose 30-35 Gy); * 7 fractions (single dose 5 Gy, total dose 35 Gy). * Whole-brain radiotherapy (WBRT): conventional fractionated radiation to the entire brain.

  • OtherCombined Local Treatment Modalities

    Patients in this cohort received a combination of local treatment approaches. This includes: * NRS with postoperative WBRT; * NRS with postoperative SRT/SRS; * Preoperative SRS followed by NRS; * Combination radiotherapy (SRS and WBRT, SRT and WBRT, SRS and SRT)

  • OtherNo Local Treatment

    Patients in this cohort did not receive any local treatment for their brain metastases. This may include patients receiving best supportive care (BSC) (typically includes the administration of corticosteroids for symptomatic control of peritumoral edema and neurological symptoms) or systemic therapy alone. Reasons for not receiving local treatment may include poor performance status, extensive intracranial disease, or patient preference.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time from the date of brain metastasis diagnosis to the date of death from any cause or last follow-up (censored)

    Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years (censored)

  2. Time to Intracranial Progression (TTIP)

    Time from the date of initial colorectal cancer diagnosis to the date of first brain metastasis detection. Based on this interval, patients will be categorized as synchronous (≤ 60 days from primary diagnosis) or metachronous (\> 60 days).

    Time frame: From date of initial cancer diagnosis until first brain metastasis detection, assessed up to 10 years

  3. Central Nervous System Progression-Free Survival (CNS-PFS)

    Time from the date of first local treatment for brain metastases to the date of subsequent intracranial progression or last instrumental follow-up (censored). Intracranial progression includes: continued growth of treated lesion (≤ 6 months after treatment), local recurrence of treated lesion (\> 6 months after treatment), or development of new intracranial lesions.

    Time frame: From the date of first local treatment for BM until subsequent intracranial progression or last imaging follow-up, assessed up to 5 years (censored)

Secondary outcomes

  1. Overall Survival from Initial Diagnosis

    Time from the date of initial colorectal cancer diagnosis to the date of death from any cause or last follow-up.

    Time frame: From date of initial cancer diagnosis until death or last contact, assessed up to 5 years

  2. Cancer-Specific Survival

    Time from brain metastasis diagnosis to death from cancer progression (intracranial and/or extracranial), with death from other causes treated as a competing event

    Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years

  3. Cumulative Incidence of Death from Intracranial Progression

    Death directly attributable to neurological complications resulting from progressive intracranial disease, analyzed using competing risks methodology with death from other causes as competing events.

    Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years

  4. Cumulative Incidence of Death from Extracranial Progression

    Death attributable to systemic disease progression in the presence of controlled intracranial disease, analyzed using competing risks methodology with death from other causes as competing events.

    Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years

  5. Cumulative Incidence of Death from Non-cancer Causes

    Death from causes unrelated to cancer progression, analyzed using competing risks methodology with cancer-related deaths as competing events.

    Time frame: From date of brain metastasis diagnosis until death or last contact, assessed up to 5 years

  6. Cumulative Incidence of Repeat Local Interventions

    The cumulative proportion of patients undergoing any additional local treatment (neurosurgery or radiotherapy) for intracranial disease progression following initial local therapy. This endpoint captures the total burden of repeat procedures required for recurrent or new intracranial lesions during follow-up. Death without a repeat intervention is treated as a competing event in the analysis

    Time frame: From date of first local treatment until the date of second local intervention or last follow-up, assessed up to 5 years (censored)

07

Study locations

15 sites
  • Gomel Regional Clinical Oncology Dispensary (OKOD)
    Homyel, 246012, Belarus
  • Kaliningrad Regional Clinical Oncology Center
    Kaliningrad, 236016, Russia
  • Moscow Regional Oncology Hospital No. 62
    Krasnogorsk, 143442, Russia
  • A.S. Loginov Moscow Clinical Scientific Center
    Moscow, 111123, Russia
  • S.S. Yudin City Clinical Hospital, Oncology Center No. 1
    Moscow, 115446, Russia
  • Blokhin's Russian Cancer Research Center
    Moscow, 115478, Russia
  • OncoStop CyberKnife Center
    Moscow, 115478, Russia
  • Moscow Multidisciplinary Clinical Center "Kommunarka"
    Moscow, 117303, Russia
  • Gamma Knife Center Moscow
    Moscow, 125047, Russia
  • N.N. Burdenko National Medical Research Center of Neurosurgery
    Moscow, 125047, Russia
  • P.A. Hertsen Moscow Oncology Research Institute
    Moscow, 125284, Russia
  • N.V. Sklifosovsky Research Institute for Emergency Medicine
    Moscow, 129090, Russia
  • N.N. Petrov National Medical Research Center of Oncology
    Saint Petersburg, 197758, Russia
  • Federal Center of Neurosurgery
    Tyumen, 625062, Russia
  • Republican Clinical Oncology Dispensary (RCOD)
    Ufa, 450054, Russia
08

References and documents

Publications

  • 33P Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1). Khalafyan, D. et al. ESMO Open, Volume 9, 103779
  • 484P. Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1): second interim analysis. Halafyan, D. et al. Annals of Oncology, Volume 35, S1582

Individual participant data

Plan to share: Yes — De-identified individual participant data collected for this study, including data dictionaries, will be available upon reasonable request from the corresponding author beginning 6 months after publication and ending 5 years following article publication. Data will be shared with researchers who provide a methodologically sound proposal for use approved by an independent review committee. Proposals should be directed to the corresponding author.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Individual participant data and supporting information will become available 6 months after publication of the primary results and will remain available for 5 years following article publication.

Access criteria: Access will be granted to qualified academic researchers who submit a methodologically sound research proposal for use approved by an independent review committee.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Mar 4, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07448662
Lead sponsor
Blokhin's Russian Cancer Research Center
Responsible party
David Khalafyan (Principal Investigator, MD, Blokhin's Russian Cancer Research Center) — Principal investigator
First posted
Mar 4, 2026
Start date
Feb 1, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

David Khalafyan, MD
principal investigator · Blokhin's Russian Cancer Research Center
Alexey Tryakin, MD, professor
study chair · Blokhin's Russian Cancer Research Center
Ali Bekyashev, MD, professor
study chair · Blokhin's Russian Cancer Research Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion